Urovant Sciences Launches GEMTESA® (vibegron) for Overactive Bladder Treatment in the U.S.
• Urovant Sciences has commercially launched GEMTESA® (vibegron) 75 mg tablets in the U.S. for treating overactive bladder (OAB) symptoms in adults.
• GEMTESA, a beta-3 adrenergic receptor agonist, is the first new oral branded OAB medication in nearly a decade, offering a novel treatment option.
• Clinical studies demonstrated that GEMTESA significantly reduces key OAB symptoms compared to placebo, without association to cognitive decline.
• Approximately 30 million Americans suffer from OAB, highlighting the importance of new treatments like GEMTESA to improve daily activities.
© Copyright 2025. All Rights Reserved by MedPath